Fibroblast Growth Factors 19 and 21 (FGF19 and FGF21) are novel endocrine messengers that regulate multiple aspects of energy homeostasis. The magnitude and pleotropic character of their beneficial actions on many, if not all abnormalities of the metabolic syndrome in animals led to extensive exploration of their biology and coordinated efforts to design novel FGF19/21-based analogs for therapeutic purposes.

While initial attempts to develop such medicines were primarily focused on improving hyperglycemia in type 2 diabetes patients, the robust, consistent and durable effects on lipid metabolism in human trials gradually transformed clinical emphasis for these factors toward their use for non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). In this review, we will communicate an overview of FGF19 and FGF21 biology and the basic mechanisms of their action, that will be followed by in-depth analysis of the recent developments with FGF21/19-based analogs in the clinic

成纤维细胞生长因子 19 和 21（FGF19 和 FGF21）是新型内分泌信使，可调节能量稳态的多个方面。它们对动物代谢综合征的许多（如果不是全部）异常的有益作用的幅度和多效性导致对其生物学的广泛探索和协调努力设计用于治疗目的的新型基于 FGF19/21 的类似物。

虽然开发此类药物的最初尝试主要集中在改善 2 型糖尿病患者的高血糖，但人体试验中对脂质代谢的稳健、一致和持久的影响逐渐将这些因素的临床重点转变为将其用于非酒精性脂肪性肝炎 (NASH)和严重的高甘油三酯血症 (SHTG)。在这篇综述中，我们将概述 FGF19 和 FGF21 生物学及其作用的基本机制，然后深入分析基于 FGF21/19 的类似物在临床上的最新发展